Aviva PLC Purchases 7,376 Shares of Incyte Corporation $INCY

Aviva PLC grew its position in shares of Incyte Corporation (NASDAQ:INCY) by 6.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 120,330 shares of the biopharmaceutical company’s stock after acquiring an additional 7,376 shares during the quarter. Aviva PLC owned 0.06% of Incyte worth $8,194,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in INCY. AQR Capital Management LLC boosted its holdings in Incyte by 92.3% during the first quarter. AQR Capital Management LLC now owns 6,736,169 shares of the biopharmaceutical company’s stock worth $405,787,000 after purchasing an additional 3,233,356 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Incyte by 71.5% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 2,386,311 shares of the biopharmaceutical company’s stock worth $162,508,000 after buying an additional 995,204 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Incyte by 65.6% during the 1st quarter. Acadian Asset Management LLC now owns 2,511,872 shares of the biopharmaceutical company’s stock worth $152,062,000 after buying an additional 994,609 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Incyte during the 2nd quarter worth about $50,076,000. Finally, Victory Capital Management Inc. grew its holdings in shares of Incyte by 581.3% in the 1st quarter. Victory Capital Management Inc. now owns 813,140 shares of the biopharmaceutical company’s stock valued at $49,236,000 after acquiring an additional 693,782 shares in the last quarter. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Incyte

In other news, EVP Lee Heeson sold 3,074 shares of Incyte stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $94.02, for a total transaction of $289,017.48. Following the completion of the sale, the executive vice president owned 29,241 shares of the company’s stock, valued at approximately $2,749,238.82. This trade represents a 9.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sheila A. Denton sold 598 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $101.36, for a total transaction of $60,613.28. Following the completion of the sale, the executive vice president directly owned 26,569 shares of the company’s stock, valued at approximately $2,693,033.84. The trade was a 2.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 4,227 shares of company stock valued at $396,327 over the last 90 days. 17.80% of the stock is currently owned by corporate insiders.

Incyte Trading Up 0.1%

Shares of INCY stock opened at $108.26 on Thursday. Incyte Corporation has a 12-month low of $53.56 and a 12-month high of $109.28. The company has a market capitalization of $21.25 billion, a PE ratio of 18.13, a price-to-earnings-growth ratio of 0.70 and a beta of 0.74. The firm has a 50 day moving average price of $89.59 and a two-hundred day moving average price of $77.50. The company has a quick ratio of 2.78, a current ratio of 3.20 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on INCY shares. Wells Fargo & Company upped their target price on Incyte from $89.00 to $97.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Citigroup boosted their price target on Incyte from $88.00 to $103.00 and gave the stock a “buy” rating in a research report on Wednesday, July 30th. Royal Bank Of Canada increased their price objective on Incyte from $81.00 to $84.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Guggenheim raised shares of Incyte from a “neutral” rating to a “buy” rating and set a $125.00 target price for the company in a research note on Monday, November 3rd. Finally, UBS Group reaffirmed a “neutral” rating and set a $68.00 price target (up from $62.00) on shares of Incyte in a research report on Wednesday, July 30th. Seven research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $92.77.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.